MULTIPLE THERAPIES, ONE VIRUS.
KALIVIR is developing cutting-edge, next-generation oncolytic viral immunotherapy programs for treatment of cancer.
PRESENTATIONS
READ MORE
Nov 10, 2022 – KaliVir Immunotherapeutics Announces Pre-Clinical Data for Oncolytic Therapy VET3-TGI at the Society for Immunology of Cancer (SITC) 37th Annual Meeting
READ MORE
NEWS AND EVENTS
Novel Vaccinia Enhanced Template (VET) Oncolytic Platform LEARN MORE
